Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 87Recurrence 17Neoplasms 6Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Sarcoma, Kaposi 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Chromosome 17 deletion 2Burkitt Lymphoma 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1Plasmacytoma 1Plasmablastic Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Hematologic Neoplasms 1Epstein-Barr Virus Infections 1

Interventions

Etoposide 3daratumumab 2Vincristine 2Prednisone 2Doxorubicin 2Cyclophosphamide 2varlilumab 1prednylidene 1pomalidomide 1deltacortene 1carmustine, poliferprosan 20 drug combination 1belantamab mafodotin 1Specimen Handling 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Melphalan 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Dexamethasone 1Cytarabine 1Carmustine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmablastic Lymphoma × pomalidomide × 1 year × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡